People given antivenoms against mamba bites often initially get better, only to start experiencing effects of the venom again, often with fatal consequences. New research reveals the reason and offers a path to life-saving solutions, but leaves questions about snake family relationships unanswered.<\/p>\n
Black mambas<\/a> have a deadly enough reputation to feature in songs<\/a> from the other side of the world. Africa also has three species of green mamba. Professor Bryan Fry<\/a> of the University of Queensland told IFLScience, \u201cCobras and puffadders bite more people, but mambas have a higher mortality rate, despite the fact that polyvalent antivenoms all include them.\u201d\u00a0<\/p>\n That\u2019s in large part because people given the antivenoms frequently die, despite showing initial improvement. Fry and colleagues have revealed that for three mamba species, the venoms can kill in two ways, and existing antivenoms only treat one.<\/p>\n \u201cThe Black Mamba, Western Green Mamba, and Jameson’s Mamba snakes aren\u2019t just using one form of chemical weapon; they\u2019re launching a coordinated attack at two different points in the nervous system,\u201d Fry said in a statement<\/a>.\u00a0<\/p>\n Initially, the venom causes flaccid paralysis by damaging the postsynaptic nervous system. Existing antivenoms<\/a> can treat this. However, initial recovery reverses because other molecules cause spastic paralysis, which was masked by the other components. \u201cWe previously thought the fourth species of mamba, the Eastern green mamba, was the only one capable of causing spastic paralysis,\u201d Fry said.\u00a0<\/p>\n Both forms of paralysis can have harmful effects on the limbs, but these will pass with time. Unfortunately, time is something victims of the bites seldom have, because either paralysis stops breathing; in one case leaving muscles without the strength to move the diaphragm, in the other locking the diaphragm in a contracted state. Fry told IFLScience that if placed on an artificial respirator, victims will recover but they\u2019re in short supply where the snakes are most common. \u201cIt\u2019s not like you can share a respirator, half an hour for you, half an hour for me,\u201d Fry noted.<\/p>\n \u201cWithout antivenom or artificial respiration, the chances of survival are among the lowest of all snake bites,\u201d Fry told IFLScience. Humans are not mamba\u2019s prey, they just want us to leave them alone, but their venom has evolved for killing birds. That\u2019s a task that requires extreme speed, lest the bitee fly away. It\u2019s no good to the biter if the bird dies elsewhere, beyond its reach.<\/p>\n Our larger bodies are only limited protection against something that potent.<\/p>\n Fry\u2019s team tested the effects of three existing commercial antivenoms. None of them are effective against the Eastern green mamba venom, nor against the spastic component of the other snakes\u2019 venom, contributing to 30,000 deaths a year from mamba bites.<\/p>\n From a practical perspective, Fry told IFLScience the initial approach should be to enrich antivenoms designed to tackle all African snakes with antibodies for Eastern Green Mamba and see if that provides protection against all four. \u201cThere\u2019s no guarantee it will work, but it\u2019s the obvious first step,\u201d Fry said.<\/p>\n \u201cThis is a good time to do it,\u201d Fry noted. \u201cThere are several players making new polyvalent antivenoms. We\u2019ve shared our results with those companies.\u201d Unfortunately, Fry acknowledged, those projects were underwritten by USAID, the closing of which may prevent them from ever reaching the market.\u00a0<\/p>\n Moreover, Fry noted, even if the suggested approach works, it will raise the cost of the antivenom, not just against mambas, but against snakes that bite more people. Already, many Africans die from snakebites for which effective antivenoms exist because they can\u2019t afford the antivenom.<\/p>\n Moreover, as first author Lee Jones said, \u201cWe also found the venom function of the mambas was different depending on their geographic location, particularly within populations of the black mamba from Kenya and South Africa. This further complicates treatment strategies across regions because the antivenoms are not developed to counteract the intricacies of the different venoms.\u201d<\/p>\n The findings confirm Fry\u2019s expectation that there will never be a universal antivenom, and his views that claims that one is close<\/a>\u00a0are based on bad science.\u00a0<\/p>\n On a more basic level, the study raises the question of why the Eastern green mamba is the odd snake out at the family venom party. \u201cWe expected the black mamba to be different from the greens,\u201d Fry said. \u201cBut that\u2019s OK, we like being surprised. It\u2019s the sign of a good study when it raises as many questions as it answers.\u201d<\/p>\n The Eastern green mamba is not thought to be the original, with the doubled-up venom developed later. In fact, the Eastern green is the most closely related to the black mamba of the three green species.<\/p>\n Fry said, \u201cWith this information we can try to find differences\u201d in behavior, prey, and habitat between the Eastern green and the other mambas, \u201cto see what sets it apart from the others.\u201d Close observation, however, carries obvious risks.<\/p>\n